High-dose chemotherapy for breast cancer

JAMA

Volumn 282, Issue 18, 1999, Pages 1701-1703

  Antman, Karen H ^a,c   Heitjan, Daniel F ^a   Hortobagyi, Gabriel N ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MHB 6N 435   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOXANTRONE; TAMOXIFEN; THIOTEPA;

BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA; MYELODYSPLASIA; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033544288     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.18.1701     Document Type: Review

References (19)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-11.
2. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995. Cancer. 1998;82:1197-1207.
3. Clark G, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence. J Clin Oncol. 1987;5:55-61.
4. Mick R, Begg CB, Antman K, Korzun AH, Frei E III. Diverse prognosis in metastatic breast cancer. Breast Cancer Res Treat 1989;13:33-38.
5. Greenberg P, Hortobagyi C, Smith T, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14: 2197-2205.
6. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585-594.
7. Antman K, Rowlings P, Vaughn W, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.
8. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med. 1995;332:901-906.
9. Peters WP, Rosner C, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkyating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes. Proc Am Soc Clin Oncol. 1999; 18:1A.
10. Bezwoda WR. Randomised, controlled trial of high-dose chemotherapy versus standard dose chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol. 1999;18:2A.
11. Rodenhuis S, Richel KJ, Wall E, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 1998;352:515-521.
12. Hortobagyi GN, Buzdar AU, Champlin R, et al. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol. 1998;17:12.
13. Bergh J. Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol. 1999;18:2A.
14. Stadtmauer EA, O'Neill A, Goldstein U, et al. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy. Proc Am Soc Clin Oncol. 1999;18:1A.
15. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483-2489.
16. Bezwoda WR. Primary high-dose chemotherapy for metastatic breast cancer: update and analysis of prognostic factors. Proc Am Soc Clin Oncol. 1998;17:115A.
17. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer results of the French protocol Pegase 04. Proc Am Soc Clin Oncol. 1999;18:43A.
18. Peters W, Jones R, Vredenburgh J, et al. A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol. 1996;15:121.
19. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177.